The Technical Analyst
Stayble Therapeutics AB [STABL.ST]
Exchange: STO Sector: Healthcare Industry: Biotechnology
Stayble Therapeutics AB Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.31% SEK0.250
America/New_York / 17 mai 2024 @ 11:23
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.91 mill |
| EPS: | -1.010 |
| P/E: | -0.250 |
| Earnings Date: | May 31, 2024 |
| SharesOutstanding: | 31.72 mill |
| Avg Daily Volume: | 0.162 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.250 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.250 | industry: PE 491.84 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK0.513 (105.81%) SEK0.264 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 0.223 - 0.277 ( +/- 10.82%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - SEK0.250
Forecast 2: 16:00 - SEK0.250
Forecast 3: 16:00 - SEK0.250
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | SEK0.250 (-5.31% ) |
| Volume | 0.0492 mill |
| Avg. Vol. | 0.162 mill |
| % of Avg. Vol | 30.47 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For STABL.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
STABL.ST
Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.